BioSpace News Archive

Xeris Biopharma Holdings, Inc. today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism.

IMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.

REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“ Revive ” or the “ Company ”) announces that it is expanding its previously announced private placement (see November 30, 2022 press release) to investors resident in the Province of Quebec.

NanoVibronix, Inc. announced that the Company’s 2022 annual meeting of stockholders (the “Annual Meeting”) was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the appointment of Paul Spence as Chief Commercial Officer.

Ocugen, Inc. announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 —for the treatment of retinitis pigmentosa and Leber congenital amaurosis.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive allosteric modulator, in adults living with schizophrenia in The Lancet.

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, has announced plans to launch a new neuroscience institute that will accelerate translational research of the brain by facilitating interaction between basic and clinical scientists and enhancing collaborative research across the UMSOM and University of Maryland, Baltimore campus.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share.